Doctors may be able to predict the likelihood of postpartum depression, Johns Hopkins researchers believe, by using a blood test that screens for two mutated genes. They studied mice and 52 pregnant women to identify the epigenetic biomarkers in question.
Harvesting neurons from the nose through a routine biopsy could allow for a speedy, accurate way to definitively diagnose schizophrenia in living patients, scientists from Tel Aviv University in Israel and Johns Hopkins University in Baltimore, MD, have discovered.
Researchers at Australia's national science agency believe their effort to develop a blood test to detect early-stage Alzheimer's has reached a major milestone.
Researchers in Singapore and colleagues across Asia made two major advances in lymphoma diagnostics that offers both bad and good news.
In the face of declining demand for diagnostic tests, LabCorp is focusing on its testing unit, signing a lab services and biomarker study deal with Bristol-Myers Squibb.
With a five-year survival rate of less than 5%, pancreatic cancer is aggressive, deadly and an all-but-certain death sentence, in part because it is usually metastasized before doctors spot it. Japanese scientists have come up with a blood test that would screen for certain metabolites to help detect the disease earlier than current diagnostics allow, and potentially boost those survival odds.
Abbott Laboratories may face a rocky FDA road for its MitraClip device, but the company won agency approval for a new molecular diagnostic that can help detect testicular cancer and prenatal problems.
Work is under way on a diagnostic test that would determine the response of a patient with advanced breast cancer to drug treatment, by measuring the DNA that breaks off from dying tumor cells into the bloodstream.
The Icahn School of Medicine at Mount Sinai in New York City has received more than $5 million from the National Institutes of Health to study the causes and pathology of spasmodic dysphonia (SD), a rare neurological disorder that causes vocal cord spasms, in hopes of finding new drug targets.
Merck is pressing forward with its controversial Alzheimer's treatment, and now it has signed a deal with Luminex ($LMNX) to develop a companion diagnostic that will screen patients for its ongoing clinical program.